259 related articles for article (PubMed ID: 18332167)
1. Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.
Wyles DL; Kaihara KA; Schooley RT
Antimicrob Agents Chemother; 2008 May; 52(5):1862-4. PubMed ID: 18332167
[TBL] [Abstract][Full Text] [Related]
2. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.
Mathy JE; Ma S; Compton T; Lin K
Antimicrob Agents Chemother; 2008 Sep; 52(9):3267-75. PubMed ID: 18591281
[TBL] [Abstract][Full Text] [Related]
3. ACH-806, an NS4A antagonist, inhibits hepatitis C virus replication by altering the composition of viral replication complexes.
Yang W; Sun Y; Hou X; Zhao Y; Fabrycki J; Chen D; Wang X; Agarwal A; Phadke A; Deshpande M; Huang M
Antimicrob Agents Chemother; 2013 Jul; 57(7):3168-77. PubMed ID: 23629709
[TBL] [Abstract][Full Text] [Related]
4. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
[TBL] [Abstract][Full Text] [Related]
5. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
Yang W; Zhao Y; Fabrycki J; Hou X; Nie X; Sanchez A; Phadke A; Deshpande M; Agarwal A; Huang M
Antimicrob Agents Chemother; 2008 Jun; 52(6):2043-52. PubMed ID: 18411324
[TBL] [Abstract][Full Text] [Related]
6. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
Gottwein JM; Jensen SB; Serre SB; Ghanem L; Scheel TK; Jensen TB; Krarup H; Uzcategui N; Mikkelsen LS; Bukh J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
[TBL] [Abstract][Full Text] [Related]
7. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
McCown MF; Rajyaguru S; Le Pogam S; Ali S; Jiang WR; Kang H; Symons J; Cammack N; Najera I
Antimicrob Agents Chemother; 2008 May; 52(5):1604-12. PubMed ID: 18285474
[TBL] [Abstract][Full Text] [Related]
8. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase.
Tomei L; Altamura S; Paonessa G; De Francesco R; Migliaccio G
Antivir Chem Chemother; 2005; 16(4):225-45. PubMed ID: 16130521
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
10. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.
Devogelaere B; Berke JM; Vijgen L; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Nyanguile O; Tahri A; Amssoms K; Lenz O; Cummings MD; Clayton RF; Vendeville S; Raboisson P; Simmen KA; Fanning GC; Lin TI
Antimicrob Agents Chemother; 2012 Sep; 56(9):4676-84. PubMed ID: 22710121
[TBL] [Abstract][Full Text] [Related]
11. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
[TBL] [Abstract][Full Text] [Related]
12. A review of HCV protease inhibitors.
Chen KX; Njoroge FG
Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
[TBL] [Abstract][Full Text] [Related]
13. Allosteric inhibitors of the NS3 protease from the hepatitis C virus.
Abian O; Vega S; Sancho J; Velazquez-Campoy A
PLoS One; 2013; 8(7):e69773. PubMed ID: 23936097
[TBL] [Abstract][Full Text] [Related]
14. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
Rawal RK; Katti SB; Kaushik-Basu N; Arora P; Pan Z
Bioorg Med Chem Lett; 2008 Dec; 18(23):6110-4. PubMed ID: 18947995
[TBL] [Abstract][Full Text] [Related]
15. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
Fenaux M; Eng S; Leavitt SA; Lee YJ; Mabery EM; Tian Y; Byun D; Canales E; Clarke MO; Doerffler E; Lazerwith SE; Lew W; Liu Q; Mertzman M; Morganelli P; Xu L; Ye H; Zhang J; Matles M; Murray BP; Mwangi J; Zhang J; Hashash A; Krawczyk SH; Bidgood AM; Appleby TC; Watkins WJ
Antimicrob Agents Chemother; 2013 Feb; 57(2):804-10. PubMed ID: 23183437
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Ando I; Adachi T; Ogura N; Toyonaga Y; Sugimoto K; Abe H; Kamada M; Noguchi T
Antimicrob Agents Chemother; 2012 Aug; 56(8):4250-6. PubMed ID: 22615294
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
[TBL] [Abstract][Full Text] [Related]
18. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
Pillaiyar T; Namasivayam V; Manickam M
Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
[TBL] [Abstract][Full Text] [Related]
19. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
Chen KX; Njoroge FG
Prog Med Chem; 2010; 49():1-36. PubMed ID: 20855037
[No Abstract] [Full Text] [Related]
20. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
